Osteoporosis International

, Volume 22, Issue 11, pp 2789–2798 | Cite as

Towards a diagnostic and therapeutic consensus in male osteoporosis

  • J. A. KanisEmail author
  • G. Bianchi
  • J. P. Bilezikian
  • J.-M. Kaufman
  • S. Khosla
  • E. Orwoll
  • E. Seeman
Position Paper



The consensus views on osteoporosis in men are reported.


A workshop was convened within a meeting on osteoporosis in men to identify areas of consensus amongst the panel (the authors) and the participants of the meeting.


A public debate with an expert panel on preselected topics was conducted.

Results and Conclusions

Consensus views were reached on diagnostic criteria and several aspects on the pathophysiology and treatment of osteoporosis in men.


Bone mineral density Bone quality Fracture risk Gonadal hormone status Obesity Testosterone Treatment T-score 


Competing interests

JAK has nothing to declare for FRAX and the context of this paper but has numerous ad hoc consultancies for governmental, non-governmental agencies and the pharmaceutical industry. GB and ES have no competing interests with regard to this manuscript. SK is a member of the advisory board for Amgen. JPB is a consultant for Amgen.


  1. 1.
    World Health Organization (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Technical report series 843. WHO, GenevaGoogle Scholar
  2. 2.
    Kanis JA, Melton LJ, Christiansen C, Johnston CC, Khaltaev N (1994) The diagnosis of osteoporosis. J Bone Miner Res 9:17–1141Google Scholar
  3. 3.
    Kanis JA, McCloskey EV, Johansson H, Oden A, Melton LJ, Khaltaev N (2008) A reference standard for the description of osteoporosis. Bone 42:467–475PubMedCrossRefGoogle Scholar
  4. 4.
    Kanis JA, Glüer CC, for the Committee of Scientific Advisors, International Osteoporosis Foundation (2000) An update on the diagnosis and assessment of osteoporosis with densitometry. Osteoporos Int 11:192–202PubMedCrossRefGoogle Scholar
  5. 5.
    Melton LJ III, Atkinson EJ, O’Connor MK, O’Fallon WM, Riggs BL (1998) Bone density and fracture risk in men. J Bone Miner Res 13:1915–1923PubMedCrossRefGoogle Scholar
  6. 6.
    Melton LJ III, Orwoll ES, Wasnich RD (2001) Does bone density predict fractures comparably in men and women? Osteoporos Int 12:707–709PubMedCrossRefGoogle Scholar
  7. 7.
    Cummings SR, Cawthon PM, Ensrud KE et al (2006) BMD and risk of hip and nonvertebral fractures in older men: a prospective study and comparison with older women. J Bone Miner Res 21:1550–6PubMedCrossRefGoogle Scholar
  8. 8.
    Johnell O, Kanis JA, Oden A et al (2005) Predictive value of bone mineral density for hip and other fractures. J Bone Miner Res 20:1185–1194PubMedCrossRefGoogle Scholar
  9. 9.
    Kanis JA, Johnell O, Oden A, De Laet C, Mellstrom D (2001) Diagnosis of osteoporosis and fracture threshold in men. Calcif Tissue Int 69:218–221PubMedCrossRefGoogle Scholar
  10. 10.
    Orwoll E (2000) Assessing bone density in men. J Bone Miner Res 15:1867–1870PubMedCrossRefGoogle Scholar
  11. 11.
    Selby PL, Davies M, Adams JE (2000) Do men and women fracture bones at similar bone densities. Osteoporos Int 11:153–157PubMedCrossRefGoogle Scholar
  12. 12.
    Lunt M, Felsenberg D, Reeve J et al (1997) Bone density variation and its effects on risk of vertebral deformity in men and women studied in thirteen European centers: the EVOS Study. J Bone Miner Res 12:1883–94PubMedCrossRefGoogle Scholar
  13. 13.
    Nguyen T, Sambrook P, Kelly P et al (1993) Prediction of osteoporotic fractures by postural instability and bone density. Br Med J 307:1111–1115CrossRefGoogle Scholar
  14. 14.
    DeLaet CED, van Hout BA, Burger H, Hoffman A, Pols HAP (1997) Bone density and risk of hip fracture in men and women: cross sectional analysis. Brit Med J 315:221–225Google Scholar
  15. 15.
    DeLaet CEDH, Van Hout BA, Burger H, Hofman A, Weel AEAM, Pols HAP (1998) Hip fracture prediction in elderly men and women: validation in the Rotterdam Study. J Bone Miner Res 13:1587–1593CrossRefGoogle Scholar
  16. 16.
    Wasnich RD, Davis JW, Ross PD (1994) Spine fracture risk is predicted by non spine fractures. Osteoporos Int 4:1–5PubMedCrossRefGoogle Scholar
  17. 17.
    Kanis JA, Johnell O, Oden A, Jonsson B, De Laet C, Dawson A (2000) Risk of hip fracture according to World Health Organization criteria for osteoporosis and osteopenia. Bone 27:585–590PubMedCrossRefGoogle Scholar
  18. 18.
    Currey JD (2002) Bones: structure and mechanics. Princeton University Press, Princeton, pp 1–380Google Scholar
  19. 19.
    Parfitt AM (2008) Skeletal heterogeneity and the purposes of bone remodeling: Implications for the understanding of osteoporosis. In: Marcus R, Feldman D, Nelson DA, Rosen CJ (eds) Osteoporosis. Academic, San Diego, pp 71–89CrossRefGoogle Scholar
  20. 20.
    Seeman E, Delmas PD (2006) Bone quality—the material and structural basis of bone strength and fragility. N Engl J Med 354:2250–61PubMedCrossRefGoogle Scholar
  21. 21.
    Lips P, Courpron P, Meunier PJ (1978) Mean wall thickness of trabecular bone packets in the human iliac crest: changes with age. Calcif Tissue Res 26:13–7PubMedCrossRefGoogle Scholar
  22. 22.
    Garnero P, Sorney-Rendu E, Duboeuf F, Delmas PD (1999) Markers of bone turnover predict postmenopausal bone loss over 4 years: the OFELY study. J Bone Miner Res 14:1614–21PubMedCrossRefGoogle Scholar
  23. 23.
    Smith MR, Goode M, Zietman AL, McGovern FJ, Lee H, Finkelstein JS (2004) Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. J Oncol 22:2546–63CrossRefGoogle Scholar
  24. 24.
    Balena R, Shih M-S, Parfitt AM (1992) Bone resorption and formation on the periosteal envelope of the ilium: a histomorphometric study in healthy women. J Bone Miner Res 7:1475–1482PubMedCrossRefGoogle Scholar
  25. 25.
    Aaron JE, Makins NB, Sagreiya K (1987) The microanatomy of trabecular bone loss in normal aging men and women. Clin Orthop Relat Res 215:260–71PubMedGoogle Scholar
  26. 26.
    Zebaze R, Ghasem-Zadeh A, Bohte A et al (2010) Intracortical remodeling and porosity: rational targets for fracture prevention. Lancet 375:1729–36PubMedCrossRefGoogle Scholar
  27. 27.
    Burghardt AJ, Buie HR, Laib A, Majumdar S, Boyd SK (2010) Rreproducibility of direct quantitative measures of cortical bone microarchitecture of the distal radius and tibia by HR-pQCT. Bone 47:519–28PubMedCrossRefGoogle Scholar
  28. 28.
    Burghardt AJ, Kazakia GJ, RamachandranS LTM, Majumdar S (2010) Age- and gender-related differences in the geometric properties and biomechanical significance of intracortical porosity in the distal radius and tibia. J Bone Miner Res 25:983–93PubMedCrossRefGoogle Scholar
  29. 29.
    Bass S, Delmas PD, Pearce G, Hendrich E, Tabensky A, Seeman E (1999) The differing tempo of growth in bone size, mass and density in girls is region-specific. J Clin Invest 104:795–804PubMedCrossRefGoogle Scholar
  30. 30.
    Duan Y, Wang XF, Evans A, Seeman E (2005) Structural and biomechanical basis of racial and sex differences in vertebral fragility in Chinese and Caucasians. Bone 36:987–98PubMedCrossRefGoogle Scholar
  31. 31.
    Riggs BL, Melton LJ III, Robb RA et al (2004) A population-based study of age and sex differences in bone volumetric density, size, geometry and structure at different skeletal sites. J Bone Miner Res 19:1945–54PubMedCrossRefGoogle Scholar
  32. 32.
    Seeman E (2003) Periosteal bone formation—a neglected determinant of bone strength. N Engl J Med 349:320–3PubMedCrossRefGoogle Scholar
  33. 33.
    Ural A, Vashishth D (2006) Interactions between microstructural and geometrical adaptation in human cortical bone. J Orthop Res 24:1489–98PubMedCrossRefGoogle Scholar
  34. 34.
    Nalla RK, Kruzic JJ, Kinney JH et al (2010) Role of microstructure in the aging-related deterioration of the toughness of human cortical bone. Mater Sci Eng, C 26:1251–1260CrossRefGoogle Scholar
  35. 35.
    Yeni YN, Brown CU, Wang Z, Norman TL (1997) The influence of bone morphology on fracture toughness of the human femur and tibia. Bone 21:453–9PubMedCrossRefGoogle Scholar
  36. 36.
    Currey JD (1988) The effect of porosity and mineral content on the Young’s modulus of elasticity of compact bone. J Biomech 21:131–139PubMedCrossRefGoogle Scholar
  37. 37.
    Ciarelli TE, Fyhrie DP, Parfitt AM (2003) Effects of vertebral bone fragility and bone formation rate on the mineralization levels of cancellous bone from white females. Bone 32:311–5PubMedCrossRefGoogle Scholar
  38. 38.
    Qiu S, Rao DS, Fyhrie DP, Palnitkar S, Parfitt AM (2005) The morphological association between microcracks and osteocyte lacunae in human cortical bone. Bone 37:10–15PubMedCrossRefGoogle Scholar
  39. 39.
    Zebaze R, Seeman E, Ghasem-Zadeh A et al (2010) Analysis system and method. Australian Provisional Patent No. 2009904407Google Scholar
  40. 40.
    Saito M, Marumo K (2010) Collagen cross-links as a determinant of bone quality: a possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus. Osteoporos Int 21:195–214PubMedCrossRefGoogle Scholar
  41. 41.
    Tang SY, Zeenath U, Vashishth D (2007) Effects of non-enzymatic glycation on cancellous bone fragility. Bone 40:1144–51PubMedCrossRefGoogle Scholar
  42. 42.
    Duan Y, Seeman E, Turner CH (2001) The biomechanical basis of vertebral body fragility in men and women. J Bone Miner Res 16:2276–2283PubMedCrossRefGoogle Scholar
  43. 43.
    Orwoll E, Ettinger M, Weiss S et al (2000) Alendronate for the treatment of osteoporosis in men. N Engl J Med 343:604–610PubMedCrossRefGoogle Scholar
  44. 44.
    Ho YV, Frauman AG, Thomson W, Seeman E (2000) Effects of alendronate on bone density in men with primary and secondary osteoporosis. Osteoporos Int 11:98–101PubMedCrossRefGoogle Scholar
  45. 45.
    Kurland ES, Cosman F, McMahon DJ, Rosen CJ, Lindsay R, Bilezikian JP (2000) Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab 85:3069–3076PubMedCrossRefGoogle Scholar
  46. 46.
    Neer RM, Arnaud CD, Zanchetta JR et al (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Eng J Med 344:1434–1441CrossRefGoogle Scholar
  47. 47.
    Orwoll ES, Scheele WH, Paul S et al (2003) The effect of teriparatide [human parathyroid hormone (1–34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 18:9–17PubMedCrossRefGoogle Scholar
  48. 48.
    Gonnell S, Cepoliano C, Montagnani A et al (2003) Alendronate treatment in men with primary osteoporosis: a three-year longitudinal study. Calcif Tissue Int 73:133–159CrossRefGoogle Scholar
  49. 49.
    Drake WM, Kendler DL, Rosen CJ, Orwoll ES (2003) An investigation of the predictors of bone mineral density and response to therapy with alendronate in osteoporotic men. J Clin Endocrinol Metab 88:5759–5765PubMedCrossRefGoogle Scholar
  50. 50.
    Miller PD, Schnitzer T, Emkey R et al (2004) Weekly oral alendronic acid in male osteoporosis. Clin Drug Invest 24l:333–341CrossRefGoogle Scholar
  51. 51.
    Boonen S, Orwoll ES, Wenderoth D, Stoner KJ, Eusebio R, Delmas PD (2009) Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study. J Bone Miner Res 24:719–725PubMedCrossRefGoogle Scholar
  52. 52.
    Ringe JD, Farahmand P, Faber K, Dorst A (2009) Sustained efficacy of risedronate in men with primary and secondary osteporoosis: results of a 2-year study. Rheumatol Int 29:311–315PubMedCrossRefGoogle Scholar
  53. 53.
    Orwoll ES, Miller PD, Adachi JD et al (2010) Efficacy and safety of a once-yearly i.v. infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study. J Bone Miner Res 25:2239–2250PubMedCrossRefGoogle Scholar
  54. 54.
    Orwoll ES, Binkley NC, Lweiecki EM, Gruntmanis U, Fries MA, Dasic G (2010) Efficacy and safety of monthly ibandronate in men with low bone density. Bone 46:970–976PubMedCrossRefGoogle Scholar
  55. 55.
    Boonen S, Kaufman JM, Reginster J-Y et al (2011) Antifracture efficacy and safety of once-yearly zoledronic acid 5 mg in men with osteoporosis: a prospective, randomised, controlled trial. Osteoporos Int 22 (Suppl 1):S180Google Scholar
  56. 56.
    Smith MR, Egerdie B, Hernández Toriz N, Denosumab HALT Prostate Cancer Study Group et al (2009) Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 361:745–55PubMedCrossRefGoogle Scholar
  57. 57.
    World Health Organization (1998) Guidelines for preclinical evaluation and clinical trials in osteoporosis. WHO, GeneveGoogle Scholar
  58. 58.
    Lang T, Cauley JA, Tylavsky F, BauerD CS, Harris TB (2010) Computed tomographic measurements of thigh muscle cross-sectional area and attenuation coefficient predict hip fracture: The health, aging, and body composition study. J Bone Miner Res 25:513–519PubMedCrossRefGoogle Scholar
  59. 59.
    Lewis CE, Ewing SK, Taylor BC et al (2007) Predictors of non-spine fracture in elderly men: the MrOS study. J Bone Miner Res 22:211–219PubMedCrossRefGoogle Scholar
  60. 60.
    Cummings SR, Nevitt MC, Browner WS et al (1995) Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med 332:767–773PubMedCrossRefGoogle Scholar
  61. 61.
    Cawthon PM, Fullman RL, Marshall L et al (2008) Physical performance and risk of hip fractures in older men. J Bone Miner Res 23:1037–44PubMedCrossRefGoogle Scholar
  62. 62.
    Michael YL, Whitlock EP, Lin JS, Fu R, O'Connor EA, Gold R (2010) Primary care-relevant interventions to prevent falling in older adults: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med 153:815–825PubMedGoogle Scholar
  63. 63.
    Bischoff-Ferrari HA, Orav EJ, Dawson-Hughes B (2006) Effect of cholecalciferol plus calcium on falling in ambulatory older men and women: a 3-year randomized controlled trial. Arch Intern Med 166:424–430PubMedCrossRefGoogle Scholar
  64. 64.
    McClung MR, Geusens P, Miller PD et al (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344:333–340PubMedCrossRefGoogle Scholar
  65. 65.
    De Laet C, Kanis JA, Oden A et al (2005) Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int 16:1330–8PubMedCrossRefGoogle Scholar
  66. 66.
    Flegal KM, Carroll MD, Ogden CL et al (2010) Prevalence and trends in obesity among US adults, 1999–2008. JAMA 303:235–41PubMedCrossRefGoogle Scholar
  67. 67.
    Sundquist J, Johnansson S-E, Sundquist K (2010) Levelling off of prevalence of obesity in the adult population of Sweden between 2000/01 and 2004/05. BMC Public Health 2010:10Google Scholar
  68. 68.
    Nielson CM, Marshall LM, Adams AL et al (2010) BMI and fracture risk in older men: the osteoporotic fractures in men (MrOS) study. J Bone Miner Res 26(3):496–502CrossRefGoogle Scholar
  69. 69.
    Freitas SS, Barrett-Connor E, Ensrud KE et al (2008) Rate and circumstances of clinical vertebral fractures in older men. Osteoporos Int 19:615–623PubMedCrossRefGoogle Scholar
  70. 70.
    Khosla S, Amin S, Orwoll E (2008) Osteoporosis in men. Endocr Rev 29:441–464PubMedCrossRefGoogle Scholar
  71. 71.
    Peacock M, Koller DL, Lai D, Hui S, Foroud T, Econs MJ (2009) Bone mineral density variation in men is influenced by sex-specific and non sex-specific quantitative trait loci. Bone 45:443–448PubMedCrossRefGoogle Scholar
  72. 72.
    Khosla S, Melton LJ III, Atkinson EJ, O'Fallon WM, Klee GG, Riggs BL (1998) Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J Clin Endocrinol Metab 83:2266–2274PubMedCrossRefGoogle Scholar
  73. 73.
    Rapado A, Hawkins F, Sobrinho L et al (1999) Bone mineral density and androgen levels in elderly males. Calcif Tissue Int 65:417–21PubMedCrossRefGoogle Scholar
  74. 74.
    Falahati-Nini A, Riggs BL, Atkinson EJ, O'Fallon WM, Eastell R, Khosla S (2000) Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J Clin Invest 106:1553–1560PubMedCrossRefGoogle Scholar
  75. 75.
    Leder BZ, LeBlanc KM, Schoenfeld DA, Eastell R, Finkelstein JS (2003) Differential effects of androgens and estrogens on bone turnover in normal men. J Clin Endocrinol Metab 88:204–210PubMedCrossRefGoogle Scholar
  76. 76.
    Khosla S, Melton LJ, Atkinson EJ, O'Fallon WM (2001) Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. J Clin Endocrinol Metab 86:3555–3561PubMedCrossRefGoogle Scholar
  77. 77.
    Van Pottelbergh I, Goemaere S, Kaufman JM (2003) Bioavailable estradiol and an aromatase gene polymorphism are determinants of bone mineral density changes in men over 70 years of age. J Clin Endocrinol Metab 88:3075–3081PubMedCrossRefGoogle Scholar
  78. 78.
    Lapauw B, Taes Y, Goemaere S, Toye K, Zmierczak H-G, Kaufman J-M (2009) Anthropometric and skeletal phenotype in men with idiopathic osteoporosis and their sons is consistent with deficient estrogen action during maturation. J Clin Endocrinol Metab 94:4300–4308PubMedCrossRefGoogle Scholar
  79. 79.
    Khosla S, Melton LJ, Riggs BL (2002) Estrogen and the male skeleton. J Clin Endocrinol Metab 87:1443–1450PubMedCrossRefGoogle Scholar
  80. 80.
    Mellstrom D, Vandenput L, Mallmim H et al (2008) Older men with low serum estradiol and high serum SHBG have an increased risk of fractures. J Bone Miner Res 23:1552–1560PubMedCrossRefGoogle Scholar
  81. 81.
    Riggs BL, Melton LJ (1986) Medical progress series: involutional osteoporosis. N Engl J Med 314:1676–1686PubMedCrossRefGoogle Scholar
  82. 82.
    Smith MR (2007) Androgen deprivation therapy for prostate cancer: new concepts and concerns. Curr Opin Endocrinol Diab Obes 14:247–254CrossRefGoogle Scholar
  83. 83.
    Lowe H, Shane E (2008) Osteoporosis associated with illnesses and medications. In: Marcus R, Feldman D, Nelson DA, Rosen CJ (eds) Osteoporosis. Elsevier, San Diego, pp 1283–1314CrossRefGoogle Scholar
  84. 84.
    Stepan JJ, Lachman M, Zverina J, Pacovsky V, Baylink DJ (1989) Castrated men exhibit bone loss—effect of calcitonin treatment on biochemical indexes of bone remodeling. J Clin Endocrinol Metab 69:523–527PubMedCrossRefGoogle Scholar
  85. 85.
    Stoch SA, Parker RA, Chen LP, Bubley G, KO YJ, Vincelette A, Greenspan SL (2001) Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists. J Clin Endocrinol Metab 86:2787–2791PubMedCrossRefGoogle Scholar
  86. 86.
    Mittan D, Lee S, Miller E, Perez RC, Basler JW, Bruder JM (2002) Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab 87:3656–3661PubMedCrossRefGoogle Scholar
  87. 87.
    Shahinian VB, Kuo Y, Freeman JL, Goodwin JS (2005) Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352:154–164PubMedCrossRefGoogle Scholar
  88. 88.
    Vanderschueren D, Vandenput L, Boonen S, Lindberg MK, Bouillon R, Ohlsson C (2004) Androgens and bone. Endocr Rev 25:389–425PubMedCrossRefGoogle Scholar
  89. 89.
    Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM (2006) Testosterone therapy in adult men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 91:1995–2010PubMedCrossRefGoogle Scholar
  90. 90.
    Behre HM, Kliesch S, Leifke E, Link TM, Nieschlag E (1997) Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab 82:2386–2390PubMedCrossRefGoogle Scholar
  91. 91.
    Crawford BA, Liu PY, Kean MT, Bleasel JF, Handelsman DJ (2003) Randomized placebo-controlled trial of androgen effects on muscle and bone in men requiring long-term systemic glucocorticoid treatment. J Clin Endocrinol Metab 88:3167–3176PubMedCrossRefGoogle Scholar
  92. 92.
    Smith MR, Fallon MA, Lee H, Finkelstein JS (2004) Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab 89:3841–3846PubMedCrossRefGoogle Scholar
  93. 93.
    Michaelson MD, Kaufman DS, Lee H et al (2007) Randomized controlled trial of annual zoledronic acidto prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostatz cancer. J Clin Oncol 25:1038–1042PubMedCrossRefGoogle Scholar
  94. 94.
    Greenspan SL, Nelson JB, Trump DL, Resnick NM (2007) Effect of once weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for non-metastatic prostate cancer. Ann Intern Med 146:416–424PubMedGoogle Scholar
  95. 95.
    Kaufman JM, Vermeulen A (2005) The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev 26:833–876PubMedCrossRefGoogle Scholar
  96. 96.
    Isidori AM, Giannetta E, Greco EA, Gianfrilli D, Bonifacio V, Isidori A, Lenzi A, Fabbri A (2005) Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta analysis. Clin Endocrinol (oxf) 63:280–293CrossRefGoogle Scholar
  97. 97.
    Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh I, Holmes JH, Dlewati A, Staley J, Santanna J, Kapoor SC, Attie MF, Haddad JG Jr, Strom BL (1999) Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 84:1966–1972PubMedCrossRefGoogle Scholar
  98. 98.
    Amory JK, Watts NB, Easley KA, Sutton PR, Anawalt BD, Matsumoto AM, Bremner WJ, Tenover JL (2004) Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab 89:503–510PubMedCrossRefGoogle Scholar
  99. 99.
    Fernandez-Balsells MM, Murad MH, Lane M et al (2010) Adverse efects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab 95:2560–2575PubMedCrossRefGoogle Scholar
  100. 100.
    Basaria S, Coviello AD, Travison TG et al (2010) Adverse events associated with testosterone administration. N Engl J Med 363:109–122PubMedCrossRefGoogle Scholar
  101. 101.
    Wang C, Nieschlag E, Swerdloff R, Behre HM, Hellstrom WJ, Gooren LJ, Kaufman JM, Legros JJ, Lunenfeld B, Morales A, Morley JE, Schulman C, Thompson IM, Weidner W, Wu FC (2008) Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations. Eur J Endocrinol 159:507–14PubMedCrossRefGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2011

Authors and Affiliations

  • J. A. Kanis
    • 1
    Email author
  • G. Bianchi
    • 2
  • J. P. Bilezikian
    • 3
  • J.-M. Kaufman
    • 4
  • S. Khosla
    • 5
  • E. Orwoll
    • 6
  • E. Seeman
    • 7
  1. 1.WHO Collaborating Centre for Metabolic Bone DiseasesUniversity of Sheffield Medical SchoolSheffieldUK
  2. 2.Division of RheumatologyGenoaItaly
  3. 3.Columbia University College of Physicians and SurgeonsNew YorkUSA
  4. 4.Department of EndocrinologyGhent University HospitalGhentBelgium
  5. 5.College of Medicine, Mayo ClinicRochesterUSA
  6. 6.Bone and Mineral UnitOregon Health and Science UniversityPortlandUSA
  7. 7.Department of Endocrinology and Medicine, Austin HealthUniversity of MelbourneMelbourneAustralia

Personalised recommendations